We are live on ! Find out more

Arvinas

ARVN

Market cap $609M

9.32 USD

-0.28

2.92%

At close Updated Aug 26, 4:00 PM EDT

Pre-market

After hours

9.32

0.00

0%

1 day

-2.92%

5 days

-2.41%

1 month

13.38%

3 months

4.48%

6 months

-30.34%

Year to date

-18.74%

1 year

23.61%

5 years

-88.83%

10 years

-41.93%

About: Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Employees: 246

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 50%

Neutral 50%

Negative 0%

Zacks Investment Research

Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know

Arvinas (ARVN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript

Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript

Arvinas Q2 Earnings Call Highlights

Arvinas NASDAQ: ARVN said it is concentrating resources on its early-stage oncology and neurology pipeline after reaching several strategic milestones in the first half of 2026, including FDA approval of VEPPANU, the first approved PROTAC degrader, and an out-licensing agreement for the product with Rigel Pharmaceuticals.

Arvinas Q2 Earnings Call Highlights

Zacks Investment Research

Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates

Arvinas, Inc. (ARVN) came out with quarterly earnings of $2.58 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to a loss of $0.84 per share a year ago.

Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader ), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months – – Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn.

Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review second quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, August 4, 2026 at 8:00 a.m. ET.

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026

Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data

Arvinas NASDAQ: ARVN management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that may require broader development resources.

Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data

Arvinas to Present at Jefferies Global Healthcare Conference

NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET.

Arvinas to Present at Jefferies Global Healthcare Conference

Arvinas Employees Give Back During Company-wide Impact Day

NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across Connecticut, in the Greater Boston area, and around the country, took part in the Company's fourth Arvinas Impact Day this past Friday. This company-wide day of service brings employees together to give back to their communities through volunteer activities that will make a meaningful difference across the Greater New Haven area and beyond.

Arvinas Employees Give Back During Company-wide Impact Day

These Analysts Increase Their Forecasts On Arvinas After Q1 Results

Arvinas Inc (NASDAQ:ARVN) reported downbeat results for the first quarter on Tuesday.

These Analysts Increase Their Forecasts On Arvinas After Q1 Results

See News Rankings

Price charts implemented using Lightweight Charts™